Business Daily from THE HINDU group of publications
Monday, May 26, 2008 ePaper | Mobile/PDA Version
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Subscription

Group Sites

Update at 1500 hrs (IST)


Corporate
Cadila to market cardio tablets in US

MUMBAI: Cadila Healthcare Ltd informed the BSE that Zydus Cadila has received an approval from the USFDA to market Benazepril tablets in the US. The drug falls in the cardiovascular segment and the sales as per NDC were estimated at $301 million in 2007.

This is the 38the ANDA approval for the company.

Related Stories:
Cadila products get USFDA nod

Prev: Rupee turns stronger against dollar
Next: Premium Farm Fresh to form JV with Sydney Market

Business Line | NUS Index |

Related Topics
Alliances & Joint Ventures
Announcements
Auditing
Awards & Honours
Bonus Announcements
Company Law
Corporate Bonds
Corporate Disputes
Corporate Governance
Courts/Legal Issues
Diversification
Environment
Human Resources
Interview
IPOs
IPR
Management
Mergers & Acquisitions
New Projects
Open Offers
Outlook
Outsourcing
Overseas Borrowings
Overseas Investments
People
Performance
Preferential Allotments
Private Placement
Regulatory Bodies & Rulings
Research & Development
Restructuring
Rights Issue
Sick Units
Society & Development
Standards & Benchmarks
Taxation
Trade & Labour Unions
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line